A biopharma company was conducting a Phase III study to assess the safety and effectiveness of a new COVID-19 vaccine. They needed to identify and connect to real-world data sources that would enable observation of infection rates and adverse events beyond the period of the trial.
As a greater number of drugs are distributed through specialty channels, it is difficult to gain deep insights into the patient journey. Single data sources provide limited visibility into the complex journeys for patients on specialty therapies.
Building External Control Arms through Real-World Data – A Phase II Oncology Case Study
